Related references
Note: Only part of the references are listed.Mesonephric-like Endometrial Carcinoma Results From Immunohistochemical Screening of 300 Endometrial Carcinomas and Carcinosarcomas for This Often Overlooked and Potentially Aggressive Entity
Anne M. Mills et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2022)
Cancer statistics, 2022
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2022)
Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment
Alicia Leon-Castillo et al.
GYNECOLOGIC ONCOLOGY (2022)
Mesonephric-like Adenocarcinoma of the Female Genital Tract: From Morphologic Observations to a Well-characterized Carcinoma With Aggressive Clinical Behavior
W. Glenn McCluggage
ADVANCES IN ANATOMIC PATHOLOGY (2022)
Defining Substantial Lymphovascular Space Invasion in Endometrial Cancer
Elke E. M. Peters et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2022)
Genomic landscape of endometrial carcinomas of no specific molecular profile
Amir Momeni-Boroujeni et al.
MODERN PATHOLOGY (2022)
Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
A. Oaknin et al.
ANNALS OF ONCOLOGY (2022)
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
Nicole Concin et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2021)
MOLECULAR PROFILING OF NSMP HIGH-RISK ENDOMETRIAL CANCERS OF THE PORTEC-3 TRIAL - PROGNOSTIC REFINEMENT AND DRUGGABLE TARGETS
L. Vermij et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2021)
Clinicopathologic and Immunohistochemical Correlates of CTNNB1 Mutated Endometrial Endometrioid Carcinoma
Danielle C. Costigan et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2020)
Mesonephric-like Carcinoma of the Endometrium A Subset of Endometrial Carcinoma With an Aggressive Behavior
Elizabeth D. Euscher et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2020)
Molecular subtypes of clear cell carcinoma of the endometrium: Opportunities for prognostic and predictive stratification
Soyoun Rachel Kim et al.
GYNECOLOGIC ONCOLOGY (2020)
Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy
Alicia Leon-Castillo et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial - ANZGOG 0903
Linda Mileshkin et al.
GYNECOLOGIC ONCOLOGY (2019)
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial
Stephanie M. de Boer et al.
LANCET ONCOLOGY (2019)
A Combined Morphologic and Molecular Approach to Retrospectively Identify KRAS-Mutated Mesonephric-like Adenocarcinomas of the Endometrium
David L. Kolin et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2019)
Targeted Genomic Profiling Reveals Recurrent KRAS Mutations in Mesonephric-like Adenocarcinomas of the Female Genital Tract
Jelena Mirkovic et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2018)
Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups
Tjalling Bosse et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2018)
Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series
S. Kommoss et al.
ANNALS OF ONCOLOGY (2018)
Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study
Louis J. M. van der Putten et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2018)
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial
Stephanie M. de Boer et al.
LANCET ONCOLOGY (2018)
A Comparison of GATA3, TTF1, CD10, and Calretinin in Identifying Mesonephric and Mesonephric-like Carcinomas of the Gynecologic Tract
Jennifer Pors et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2018)
L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile
Felix K. F. Kommoss et al.
BRITISH JOURNAL OF CANCER (2018)
Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer
S. M. de Boer et al.
ANNALS OF ONCOLOGY (2018)
The genetic landscape of endometrial clear cell carcinomas
Deborah F. DeLair et al.
JOURNAL OF PATHOLOGY (2017)
CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence
Katherine C. Kurnit et al.
MODERN PATHOLOGY (2017)
Amplification of 1q32.1 Refines the Molecular Classification of Endometrial Carcinoma
Jeroen Depreeuw et al.
CLINICAL CANCER RESEARCH (2017)
Confirmation of ProMisE: A Simple, Genomics-Based Clinical Classifier for Endometrial Cancer
Aline Talhouk et al.
CANCER (2017)
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
N. Colombo et al.
ANNALS OF ONCOLOGY (2016)
Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts
Ellen Stelloo et al.
CLINICAL CANCER RESEARCH (2016)
Estrogen receptor-alpha as a predictive biomarker in endometrioid endometrial cancer
Floor J. Backes et al.
GYNECOLOGIC ONCOLOGY (2016)
Progesterone receptor expression is associated with longer overall survival within high-grade histotypes of endometrial carcinoma: A Canadian high risk endometrial cancer consortium (CHREC) study
Martin Kobel et al.
GYNECOLOGIC ONCOLOGY (2016)
A clinically applicable molecular-based classification for endometrial cancers
A. Talhouk et al.
BRITISH JOURNAL OF CANCER (2015)
Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer - A pooled analysis of PORTEC 1 and 2 trials
Tjalling Bosse et al.
EUROPEAN JOURNAL OF CANCER (2015)
Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative
Ellen Stelloo et al.
MODERN PATHOLOGY (2015)
L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: Pooled PORTEC trial results
T. Bosse et al.
EUROPEAN JOURNAL OF CANCER (2014)
Clinical Significance of CTNNB1 Mutation and Wnt Pathway Activation in Endometrioid Endometrial Carcinoma
Yuexin Liu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial
Jone Trovik et al.
EUROPEAN JOURNAL OF CANCER (2013)
Integrated genomic characterization of endometrial carcinoma
Gad Getz et al.
NATURE (2013)
The EMT signaling pathways in endometrial carcinoma
Eva Colas et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2012)
Progesterone Inhibits Epithelial-to-Mesenchymal Transition in Endometrial Cancer
Paul H. van der Horst et al.
PLOS ONE (2012)
Up-regulation of L1CAM is linked to loss of hormone receptors and E-cadherin in aggressive subtypes of endometrial carcinomas
Monica Huszar et al.
JOURNAL OF PATHOLOGY (2010)
Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer
Vincent Jongen et al.
GYNECOLOGIC ONCOLOGY (2009)
Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients:: The postoperative radiation therapy in endometrial carcinoma trial
CL Creutzberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Stage IC adenocarcinoma of the endometrium: survival comparisons of surgically staged patients with and without adjuvant radiation therapy
JM Straughn et al.
GYNECOLOGIC ONCOLOGY (2003)
Share Paper
